Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in hormone receptor–positive breast cancer, the future of antibody-drug conjugates in triple-negative breast cancer, and the importance of educating patients about their available treatment options so they can share in the decision-making process.
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
– Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months of Follow-Up –BOTHELL, Wash. (BUSINESS WIRE) #SABCS2021 Seagen Inc. (Nasdaq:SGEN) today announced the presentation.
- Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months
Seagen, Inc : Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.